NIAID-Supported HIV Vaccine Trials Network Has New Specimens Available

Funding News Edition: February 15, 2023
See more articles in this edition

Through a recent request for proposals (RFP), the HIV Vaccine Trials Network (HVTN) invites outside investigators to apply to use Imbokodo/HVTN 705 participant specimens or study data to conduct independent scientific research. 

Although the Imbokodo investigational vaccine regimen did not provide protection against HIV infection in young women at high likelihood of HIV acquisition in sub-Saharan Africa (vaccine efficacy point estimate of 14 percent with a 95 percent confidence interval that crossed zero), research is ongoing to investigate associations between vaccine efficacy and biomarkers of both humoral and cellular immunity (as described in Kenny et al., 2022).

The Imbokodo trial design included extensive, longitudinal sampling for serum and peripheral blood mononuclear cells, among other specimen types to which investigators may request access.

The announcement at Information and Resources for RFP Applicants provides further details. Note that there is no designated funding associated with this RFP. The submission period closes on April 4, 2023.

Contact Us

Email us at for help navigating NIAID’s grant and contract policies and procedures.

Content last reviewed on